InnoCare Pharma Limited (SHA:688428)

InnoCare Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,981	6,241	8,287	8,698	5,929	3,970
Trading Asset Securities	75.06	759.18	-	313.29	317.06	-
Cash & Short-Term Investments	7,056	7,000	8,287	9,011	6,246	3,970
Cash Growth	-3.32%	-15.53%	-8.04%	44.28%	57.34%	67.35%
Accounts Receivable	392.27	351	276.38	127.83	45.27	0.15
Other Receivables	0.46	0.05	31.34	61.79	62.27	78.1
Receivables	392.73	351.05	307.71	189.61	107.55	78.25
Inventory	117.75	95.58	119.09	65.32	9.92	1.88
Other Current Assets	278.07	373.56	51.38	33.56	53.87	42.46
Total Current Assets	7,845	7,820	8,765	9,300	6,417	4,092
Property, Plant & Equipment	775.4	814.27	798.5	937.27	566.08	403.13
Long-Term Investments	-	0.4	5.66	11.71	326.1	1.16
Goodwill	3.12	3.12	3.12	3.13	3.13	3.13
Other Intangible Assets	252.53	258.14	266.03	41.31	34.17	37.02
Long-Term Deferred Charges	29.11	31.94	33.3	-	-	-
Other Long-Term Assets	458.62	479.43	48.06	28.04	50.95	1.05
Total Assets	9,364	9,407	9,920	10,321	7,398	4,538
Accounts Payable	178.05	128.36	134.9	118.6	84.6	5.52
Accrued Expenses	119.97	127.52	100.06	116.03	97.5	50.21
Short-Term Debt	80.09	137.45	-	-	-	-
Current Portion of Long-Term Debt	64.28	56.35	1,256	1,197	-	-
Current Portion of Leases	29.97	31.61	23.23	20.11	20.34	6.83
Current Unearned Revenue	-	-	-	12	19.48	6.65
Other Current Liabilities	551.72	567.99	567.66	611.52	107.39	35.25
Total Current Liabilities	1,024	1,049	2,082	2,075	329.3	104.45
Long-Term Debt	1,346	1,322	331.88	287.76	1,238	1,150
Long-Term Leases	17.64	27.44	43.65	35.44	47.44	17.17
Long-Term Unearned Revenue	257.29	263	281.78	278.2	123.61	100
Long-Term Deferred Tax Liabilities	-	-	-	-	-	6.04
Total Liabilities	2,645	2,662	2,739	2,677	1,739	1,377
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	12,144	12,111	12,150	11,756	9,372	6,743
Retained Earnings	-5,550	-5,520	-5,080	-4,423	-3,536	-3,544
Treasury Stock	-9.01	-3.1	-	-	-	-
Comprehensive Income & Other	118.13	137.99	77.23	263.73	-230.85	-95.05
Total Common Equity	6,703	6,725	7,148	7,597	5,605	3,104
Minority Interest	15.09	20.63	32.86	47.23	54.36	56.49
Shareholders' Equity	6,718	6,746	7,181	7,644	5,659	3,161
Total Liabilities & Equity	9,364	9,407	9,920	10,321	7,398	4,538
Total Debt	1,538	1,575	1,655	1,540	1,306	1,174
Net Cash (Debt)	5,518	5,425	6,632	7,471	4,940	2,796
Net Cash Growth	-1.76%	-18.20%	-11.22%	51.24%	76.67%	-
Net Cash Per Share	3.39	3.20	3.89	5.05	3.62	2.89
Filing Date Shares Outstanding	1,212	1,762	1,684	1,764	1,500	1,289
Total Common Shares Outstanding	1,212	1,762	1,684	1,764	1,500	1,289
Working Capital	6,821	6,771	6,683	7,224	6,088	3,988
Book Value Per Share	5.53	3.82	4.24	4.31	3.74	2.41
Tangible Book Value	6,448	6,464	6,879	7,553	5,567	3,064
Tangible Book Value Per Share	5.32	3.67	4.08	4.28	3.71	2.38
Buildings	422.73	422.73	364.63	224.41	81.04	-
Machinery	400.51	362.86	302.01	248.13	127.57	13.91
Construction In Progress	108.78	138.86	166.91	197.65	230.72	296.93
Leasehold Improvements	-	-	-	35.44	6.68	1.08

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.